Drug Type Small molecule drug |
Synonyms DB 105, ORM-12741 |
Target |
Action antagonists |
Mechanism α2C-AR antagonists(Alpha-2c adrenergic receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Aggression | Phase 2 | Finland | 14 Aug 2015 | |
Aggression | Phase 2 | Finland | 14 Aug 2015 | |
Agitation | Phase 2 | Finland | 14 Aug 2015 | |
Agitation | Phase 2 | Finland | 14 Aug 2015 | |
Alzheimer Disease | Phase 2 | Finland | 01 Apr 2011 | |
Scleroderma, Systemic | Phase 2 | United Kingdom | 01 Mar 2011 | |
Vasospasm | Phase 2 | United Kingdom | 01 Mar 2011 | |
Raynaud Disease | Phase 2 | United Kingdom | 01 Mar 2011 | |
Schizophrenia | Phase 2 | Europe | - | |
Schizophrenia | Phase 2 | - | - |
Phase 2 | 100 | (Low Dose of ORM-12741) | ezocypmgpy = lqwdiqvwzi dhaqplcrhf (zjdfpfmhbs, tugggmnomd - splaxfogkm) View more | - | 28 Apr 2021 | ||
(High Dose of ORM-12741) | ezocypmgpy = gmgvtnwkss dhaqplcrhf (zjdfpfmhbs, tfvjcpkrhw - velcebmhsj) View more | ||||||
NCT01324518 (Pubmed) Manual | Phase 2 | 100 | etxabfgqgk(todpaoalce): P-Value = 0.030 View more | Positive | 08 Dec 2016 | ||
Placebo |